

# Lawrence Liberti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9007528/publications.pdf>

Version: 2024-02-01

15  
papers

153  
citations

1307594

7  
h-index

1199594

12  
g-index

15  
all docs

15  
docs citations

15  
times ranked

145  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions. <i>Pharmaceutical Medicine</i> , 2021, 35, 113-122.	1.9	4
2	Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?. <i>Clinical Therapeutics</i> , 2021, 43, 888-905.	2.5	2
3	Improving access to quality medicines in East Africa: An independent perspective on the East African Community Medicines Regulatory Harmonization initiative. <i>PLoS Medicine</i> , 2020, 17, e1003092.	8.4	6
4	A Baseline Analysis of Regulatory Review Timelines for ANVISA: 2013–2016. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1428-1435.	1.6	10
5	A Proposed Framework for a Globally Applicable Pragmatic Approach to Using Facilitated Regulatory Pathways. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 55-68.	1.6	5
6	An evaluation of the Caribbean regulatory system centralized assessment process for medicines submitted 2017–2018 using the OpERA methodology. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 56.	2.4	1
7	Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures—Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions. <i>Value in Health</i> , 2018, 21, 707-714.	0.3	30
8	A Proposed Framework for a Globally Applicable Pragmatic Approach to Using Facilitated Regulatory Pathways. <i>Therapeutic Innovation and Regulatory Science</i> , 2018, , 216847901881397.	1.6	2
9	Factors related to drug approvals: predictors of outcome?. <i>Drug Discovery Today</i> , 2017, 22, 937-946.	6.4	8
10	FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines. <i>Frontiers in Pharmacology</i> , 2017, 8, 161.	3.5	21
11	Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities. <i>Journal of Public Health Policy</i> , 2016, 37, 315-333.	2.0	17
12	Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications. <i>Oncologist</i> , 2015, 20, 683-691.	3.7	7
13	A Universal Framework for the Benefit-Risk Assessment of Medicines: Is This the Way Forward?. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 17-25.	1.6	25
14	Characterizing Good Review Practices: A Survey Report Among Agencies of APEC Member Economies. <i>Therapeutic Innovation and Regulatory Science</i> , 2013, 47, 678-683.	1.6	8
15	Standardizing the Benefit-Risk Assessment of New Medicines. <i>Pharmaceutical Medicine</i> , 2011, 25, 139-146.	1.9	7